erythroblastosis fetalis

(redirected from Hemolytic disease of the newborn)
Also found in: Thesaurus, Medical, Legal, Encyclopedia, Wikipedia.

erythroblastosis fe·ta·lis

 (fē-tā′lĭs)
n.
A severe hemolytic disease of a fetus or newborn infant caused by the production of maternal antibodies against the fetal red blood cells, usually involving Rh incompatibility between the mother and fetus. Also called RH disease.

[New Latin erythroblastōsis fētālis : erythroblastōsis, erythroblastosis + fētālis, fetal.]
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.erythroblastosis fetalis - severe anemia in newborn babies; the result of Rh incompatibility between maternal and fetal blood; typically occurs when the child of an Rh-negative mother inherits Rh-positive blood from the father; can be diagnosed before birth by amniocentesis
anemia, anaemia - a deficiency of red blood cells
References in periodicals archive ?
Anti-Rh(D) IgG subclasses and severity of Rh hemolytic disease of the newborn.
Hemolytic disease of the newborn occurs as a result of hemolysis and shortening of the life span of the new-born's erythrocytes because of antibodies crossing from the mother by the placenta (5).
Hemolytic disease of the newborn (Erythroblastosis fetalis) Nelson Textbook of pediatrics.
Controlled trials of the treatment of Hemolytic disease of the newborn.
1) In the 13 years since that survey was conducted, case reports of Rhpositive persons forming anti-D have continued to accumulate, (17-25) including at least 1 additional case of fatal Rh hemolytic disease of the newborn.
The jaundice was felt to be due to ABO hemolytic disease of the newborn (mother O negative, newborn B negative, direct antiglobulin test positive) and was treated successfully by a 36-h regimen of phototherapy.
Severe hemolytic disease of the newborn in a group B African-American infant delivered by a group O mother.
Rh hemolytic disease of the newborn treated with high-dose intravenous immunoglobulin and plasmapheresis.
Rozrolimupab (Sym001) is currently in phase II clinical development as a treatment of immune thrombocytopenic purpura (ITP) and as anti-D prophylaxis (ADP) to prevent hemolytic disease of the newborn (HDN).
There are many, many of these autoimmune conditions, but one that is important to respiratory therapists, and can be easily identified in the clinical laboratory is autoimmune hemolytic disease of the newborn (RhO incompatibility type).

Full browser ?